AI Engines For more Details: Perplexity Kagi Labs You
Isobutyryl-CoA Dehydrogenase Deficiency (IBDD): Isobutyric acidemia, also known as isobutyryl-CoA dehydrogenase deficiency (IBDD), is a rare inherited metabolic disorder characterized by a deficiency of the enzyme isobutyryl-CoA dehydrogenase, which is involved in the breakdown of the amino acid valine. As a result, individuals with IBDD are unable to properly metabolize valine, leading to the accumulation of isobutyric acid and its derivatives in the body. High levels of isobutyric acid can be toxic and cause symptoms such as metabolic acidosis, vomiting, poor feeding, lethargy, developmental delays, seizures, and a distinctive odor resembling sweaty feet. Without prompt treatment, IBDD can lead to life-threatening complications such as metabolic crises and neurological damage.
Ketoacidosis: In individuals with IBDD or other metabolic disorders associated with impaired valine metabolism, the accumulation of isobutyric acid and its metabolites can disrupt normal metabolic processes and lead to ketoacidosis. Ketoacidosis is a serious condition characterized by elevated levels of ketones and acidic pH in the blood, which can cause symptoms such as rapid breathing, fruity-scented breath, confusion, and coma if left untreated. Ketoacidosis requires immediate medical intervention to correct metabolic imbalances and prevent complications.
Odor Disorders: The distinctive odor associated with IBDD, often described as "sweaty feet," is caused by the accumulation of isobutyric acid and its derivatives in the body. This odor may be present in the sweat, urine, breath, and body secretions of affected individuals and can be a characteristic feature used for diagnostic purposes. However, it is important to note that not all individuals with IBDD may exhibit this odor, and other factors may contribute to body odor in different individuals.
Treatment: Management of IBDD typically involves dietary restrictions to limit the intake of valine and other branched-chain amino acids, as well as supplementation with special medical formulas designed to provide essential nutrients while minimizing the accumulation of toxic metabolites. In some cases, medications such as carnitine or antibiotics may be used to help manage symptoms and prevent metabolic crises. Regular monitoring of metabolic parameters, nutritional status, and growth is essential to optimize outcomes and prevent long-term complications in individuals with IBDD.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
| ADHD | 0.6 | 2 | -2.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 1.2 | -1 |
| Allergies | 0.4 | 0.6 | -0.5 |
| Allergy to milk products | 0.8 | 0.4 | 1 |
| Alzheimer's disease | 1 | 0.8 | 0.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | -1.4 | |
| Ankylosing spondylitis | 1 | 2.2 | -1.2 |
| Anorexia Nervosa | 0.2 | 1 | -4 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.2 | 1.4 | -6 |
| Atherosclerosis | 0.2 | 0.2 | 0 |
| Atrial fibrillation | 1.8 | 0.6 | 2 |
| Autism | 2.2 | 2.2 | 0 |
| Bipolar Disorder | 0.2 | 1.6 | -7 |
| Brain Trauma | 1.6 | 1.6 | |
| Carcinoma | 1.2 | 1.6 | -0.33 |
| Celiac Disease | 1.4 | 0.4 | 2.5 |
| Cerebral Palsy | 0.4 | 0.2 | 1 |
| Chronic Fatigue Syndrome | 1 | 2.2 | -1.2 |
| Chronic Kidney Disease | 0.6 | -0.6 | |
| Chronic Lyme | 0.2 | 0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Chronic Urticaria (Hives) | 0.2 | 0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | -0.4 | |
| Colorectal Cancer | 0.6 | 2.4 | -3 |
| Constipation | 0.8 | 1.4 | -0.75 |
| Coronary artery disease | 0.4 | -0.4 | |
| COVID-19 | 2.1 | 1.6 | 0.31 |
| Crohn's Disease | 1.2 | 1.4 | -0.17 |
| cystic fibrosis | 0.2 | 0.2 | |
| Depression | 3.4 | 4 | -0.18 |
| Eczema | 1.2 | -1.2 | |
| Endometriosis | 0.4 | 0.8 | -1 |
| Eosinophilic Esophagitis | 0.2 | 0.2 | |
| Epilepsy | 0.8 | 1.6 | -1 |
| Fibromyalgia | 0.2 | 0.4 | -1 |
| Functional constipation / chronic idiopathic constipation | 1.2 | 2.2 | -0.83 |
| gallstone disease (gsd) | 0.4 | 0.4 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| giant cell arteritis | 0.6 | -0.6 | |
| Glioblastoma | 0.2 | 0.2 | |
| Gout | 1.8 | -1.8 | |
| Graves' disease | 0.6 | 2.4 | -3 |
| Halitosis | 0.8 | -0.8 | |
| Hashimoto's thyroiditis | 0.4 | 0.4 | 0 |
| Hidradenitis Suppurativa | 0.4 | -0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.6 | -2 |
| hypercholesterolemia (High Cholesterol) | 0.4 | -0.4 | |
| hyperglycemia | 0.6 | 0.6 | 0 |
| Hyperlipidemia (High Blood Fats) | 1 | 1 | |
| hypersomnia | 0.8 | 0.8 | |
| hypertension (High Blood Pressure | 1 | 1.2 | -0.2 |
| Hypoxia | 0.2 | 0.6 | -2 |
| IgA nephropathy (IgAN) | 0.4 | 0.4 | |
| Inflammatory Bowel Disease | 0.6 | 0.4 | 0.5 |
| Insomnia | 1 | 0.8 | 0.25 |
| Intelligence | 1.4 | 1.4 | |
| Intracranial aneurysms | 0.4 | -0.4 | |
| Irritable Bowel Syndrome | 1 | 1.6 | -0.6 |
| Liver Cirrhosis | 1.2 | 1.6 | -0.33 |
| Long COVID | 6 | 2.4 | 1.5 |
| Low bone mineral density | 0.2 | 0.2 | 0 |
| Lung Cancer | 1.2 | 1.2 | |
| ME/CFS with IBS | 0.2 | 0.2 | 0 |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 2 | 2.8 | -0.4 |
| Mood Disorders | 3.4 | 5.2 | -0.53 |
| Multiple Sclerosis | 1.4 | 0.8 | 0.75 |
| myasthenia gravis | 0.2 | 0.2 | |
| Neuropathy (all types) | 0.2 | 0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 1.4 | -1.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.4 | 4.5 |
| Obesity | 2.6 | 1.4 | 0.86 |
| obsessive-compulsive disorder | 0.6 | 0.8 | -0.33 |
| Osteoarthritis | 0.2 | -0.2 | |
| Osteoporosis | 1.2 | 0.8 | 0.5 |
| pancreatic cancer | 0.2 | -0.2 | |
| Parkinson's Disease | 1.2 | 1.9 | -0.58 |
| Polycystic ovary syndrome | 1 | 1.8 | -0.8 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.2 | 0.2 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Psoriasis | 1 | 0.2 | 4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 2.2 | 0.09 |
| Schizophrenia | 0.8 | 2 | -1.5 |
| scoliosis | 0.2 | 0.2 | |
| sensorineural hearing loss | 0.6 | -0.6 | |
| Sjögren syndrome | 1 | 0.8 | 0.25 |
| Sleep Apnea | 1 | 1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | -0.2 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.6 | -2 |
| Systemic Lupus Erythematosus | 2 | 2.6 | -0.3 |
| Tic Disorder | 0.8 | 0.4 | 1 |
| Tourette syndrome | 0.2 | 0.2 | 0 |
| Type 1 Diabetes | 0.2 | 1 | -4 |
| Type 2 Diabetes | 1.6 | 2.2 | -0.38 |
| Ulcerative colitis | 3.2 | 0.8 | 3 |
| Unhealthy Ageing | 0.8 | 0.2 | 3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.